Henry E. Pelish, Chief Scientific Officer at Nuvalent, Inc. (NUVL), sold 65,490 shares at $94.80 ($6.5M) on 2024-09-16, disclosed to the SEC on 2024-09-18.
Scheduled sale ($6.5M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $93.25 | 1,966 | $183K | 2.8% |
| 2 | $93.25 | 1,966 | $183K | 2.8% |
| 3 | $94.80 | 3,754 | $356K | 5.5% |
| 4 | $94.80 | 3,754 | $356K | 5.5% |
| 5 | $95.36 | 1,548 | $148K | 2.3% |
| 6 | $95.36 | 1,548 |
| $148K |
| 2.3% |
| 7 | $96.61 | 4,105 | $397K | 6.1% |
| 8 | $96.61 | 4,105 | $397K | 6.1% |
| 9 | $97.54 | 3,197 | $312K | 4.8% |
| 10 | $97.54 | 3,197 | $312K | 4.8% |
| 11 | $98.22 | 706 | $69K | 1.1% |
| 12 | $98.22 | 706 | $69K | 1.1% |
| 13 | $100.25 | 4,094 | $410K | 6.3% |
| 14 | $100.25 | 4,094 | $410K | 6.3% |
| 15 | $101.18 | 5,513 | $558K | 8.6% |
| 16 | $101.18 | 5,513 | $558K | 8.6% |
| 17 | $102.54 | 7,812 | $801K | 12.4% |
| 18 | $102.54 | 7,812 | $801K | 12.4% |
| 19 | $102.80 | 100 | $10K | 0.2% |
| Total | $98.92 avg | 65,490 | $6.5M | 100% |
| Filing → |
| NUVL | SELL | 2026-03-16 | $3.4M | — | Filing → |
| NUVL | SELL | 2026-01-07 | $502K | — | Filing → |
| NUVL | SELL | 2025-10-17 | $2.6M | — | Filing → |